Printer Friendly

MEDIMMUNE TO ACQUIRE DISTRIBUTION RIGHTS TO CYTOGAM(TM)

 MEDIMMUNE TO ACQUIRE DISTRIBUTION RIGHTS TO CYTOGAM(TM)
 GAITHERSBURG, Md., Oct. 29 /PRNewswire/ -- MedImmune Inc. (NASDAQ: MEDI) today announced it has signed a letter of intent with the distributor of tits first product, CytoGam(TM), to acquire all product rights from the distributor. MedImmune will begin selling CytoGam(TM) through its own sales force upon execution of a definitive agreement anticipated later this year.
 "This is good news for MedImmune," said Wayne T. Hockmeyer, Ph.D., president and chief executive officer. "Building our own sales force for the CytoGam(TM) is a strategic opportunity for MedImmune which will provide us with greater flexibility and control in promoting CytoGam(TM) and will significantly enhance our ability to launch our second product, Respivir(TM) (previously called Hypermune-RSV(TM)), if and when approved by the FDA." Respivir(TM) is the subject of a product license application expected to be filed with the FDA later this year.
 MedImmune plans to build a hospital-based sales force of 12 to 15 representatives to sell CytoGam(TM). We have done extensive market research on CytoGam(TM) and believe it is a good product which can be effectively sold by a sales force of this size. Moreover, this sales force provides an important base for expansion in implementing our plans to sell Respivir(TM) in the United States, if and when approved by the FDA," added Dr. Hockmeyer.
 CytoGam(TM) is a polyclonal antibody product indicated for prevention of primary cytomegalovirus (CMV) disease associated with kidney transplantation. The product was developed by MedImmune in partnership with Massachusetts Health Research Institute and launched by MedImmune's distributor in November 1991. An application for an expanded indication for prevention of CMV disease in all solid organ transplants was filed in June 1992 and Phase I clinical trails are underway for prevention of CMV disease in AIDS patients. The initial indication being sought for Respivir(TM) is prevention of respiratory syncytial virus (RSV) infection in high risk infants. RSV is the leading cause of viral pneumonia in infants.
 The letter of intent provides for the transfer of all CytoGam(TM) product rights to MedImmune in exchange for a $4.5 million up-front payment, royalties on future sales and a commitment by MedImmune to purchase the distributor's current inventory within 18 months of the execution of a definitive agreement. Completion of the transaction is subject to certain conditions, including execution of a definitive agreement. MedImmune expects to take a one-time charge in the first quarter of 1992 of approximately $6.2 million associated with this agreement and to report a loss for the full year.
 MedImmune, Inc. was founded in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's corporate headquarters are in Gaithersburg, Md.
 -0- 10/29/92
 /CONTACT: David M. Mott, vice president business development and planning, 301-417-0770, of Anthony J. Russo, Ph.D. of Noonan Russo Communications, 212-979-9180/
 (MEDI) CO: MedImmune Inc. ST: Maryland IN: MTC SU:


LD-SM -- NY093 -- 6811 10/29/92 17:09 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 29, 1992
Words:508
Previous Article:NORTH STAR UNIVERSAL, INC. ANNOUNCES THIRD-QUARTER 1992 RESULTS
Next Article:TUBOS DE ACERO DE MEXICO REPORTS RESULTS
Topics:


Related Articles
MEDIMMUNE BEGINS STUDY OF CYTOGAM IN AIDS PATIENTS
MEDIMMUNE'S CEO REVIEWS RECENT DEVELOPMENTS
MEDIMMUNE ENTERS DISTRIBUTION AGREEMENT FOR CYTOGAM IN EASTERN EUROPE AND FORMER U.S.S.R.
MEDIMMUNE TO ACQUIRE MELVILLE BIOLOGICS FROM THE NEW YORK BLOOD CENTER FOR $40 MILLION
MEDIMMUNE RECEIVES APPROVAL TO SELL CYTOGAM IN TURKEY
MEDIMMUNE REPORTS FIRST QUARTER RESULTS
MEDIMMUNE REPORTS CYTOGAM(R) SALES UP 24 PERCENT IN FIRST QUARTER
MEDIMMUNE REPORTS PRODUCT SALES INCREASE 116% FOR Q1 1996
MedImmune Expands International Commercialization of CytoGam(R)
MedImmune and BioTransplant Announce Clinical Results at American Society of Transplantation Meeting.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters